Shopping Cart
Guide · Regenerative medicine
What is regenerative medicine?
Regenerative medicine encompasses different procedures intended to repair, replace or restore damaged cells, tissues or functions as far as possible. The field ranges from established cell therapies to approaches that are still experimental.
This article provides a factual overview of the fundamentals, procedures, PRP and regulatory issues. It does not recommend for or against any particular treatment.
FieldInterdisciplinary field, not a single therapy
AimRepair, replacement or restoration of function
Development statusFrom established to experimental
Important“Regenerative” is not a promise of efficacy
Regenerative medicine explained briefly
Regenerative medicine is not a single product or treatment. It combines medical research with cell biology, biotechnology, materials science and engineering.
Its focus is on procedures intended to repair, replace or restore the function of damaged cells, tissues or organs. Depending on the scientific classification, these include cell therapies, stem-cell approaches, tissue engineering, biomaterials, certain gene therapies and autologous biological preparations.
The term is often equated with stem cells, but that definition is too narrow. Stem-cell-based procedures are only one part of the field. Engineered scaffolds, other cell types, combination products and procedures using the body’s own signalling molecules or blood components are also relevant.
Clarification of the term
Regenerative medicine is not an alternative system opposed to conventional medicine. A procedure may form part of standard care, be used as an adjunct, be investigated in a clinical trial or still be experimental.
Repair is not automatically regeneration
The body can repair many types of damage itself. Small skin injuries close, bones may heal after fractures and blood cells are continuously renewed. This capacity differs considerably between tissues.
Repair
The defect is closed functionally
Tissue may heal stably without fully regaining its original structure. Scar tissue is a typical example.
Regeneration
Structure and function are intended to return
The aim is to restore the original tissue as far as possible. This cannot be achieved for every condition or with every procedure.
“Regenerative” therefore describes the medical objective first of all. The term alone says neither that a procedure is authorised nor that complete restoration will be achieved.
Which procedures are included?
The boundaries of the field are not defined identically everywhere. The following areas are commonly distinguished:
Cell-based procedures
Living cells are intended to replace damaged structures, influence biological processes or support specific functions. Autologous cells, donor cells or laboratory-processed cell preparations may be used.
Stem-cell-based approaches
Stem cells can multiply and, depending on their type, develop into specific cell types. Their origin, differentiation potential and medical use differ considerably.
Tissue engineering
Cells are combined with biological or synthetic scaffold structures. These scaffolds are intended to provide a three-dimensional environment for cell attachment and tissue formation.
Gene and combination therapies
Genetic information may be modified or introduced in a targeted manner. Combination products may combine cells, biomaterials, medicinal components or medical devices.
Overly simplified:
After injection, stem cells do not automatically identify every damaged structure and restore it completely. Cell survival, distribution, differentiation and interactions must be investigated for each procedure.
Where does PRP fit in?
Platelet-rich plasma, or PRP, is commonly classified as an orthobiologic or within regenerative medicine. It is prepared from the patient’s own blood. Centrifugation separates blood components and may produce a plasma fraction with a platelet proportion that differs from whole blood.
Platelets are involved in haemostasis and contain signalling proteins and other biologically active components. These participate in inflammatory, healing and remodelling processes, which is why PRP is being investigated in several medical specialties.
PRP is not a stem-cell therapy
PRP does not contain stem cells. It is an autologous preparation derived from blood. Its composition and properties depend, among other factors, on the system, tube type, centrifugation protocol and the proportions of platelets, leukocytes and erythrocytes.
No universally optimal PRP composition or protocol valid for all indications has been established. Studies therefore cannot be compared on the basis of the term “PRP” alone.
Biological plausibility is not proof of efficacy
The term “regenerative” must not be equated with guaranteed formation of healthy new tissue. Depending on the indication, a procedure may aim to influence healing processes, reduce symptoms or support functional recovery.
A procedure cannot be assessed in general terms
Whether structural regeneration occurs must be studied for the specific condition, product and protocol used. Results from laboratory or animal models cannot automatically be transferred to humans.
The evidence may also vary within one specialty. Clinical studies and consensus papers are available for some uses. In other areas, robust comparative data are lacking or the products used differ so greatly that results can only be pooled to a limited extent.
Regenerative medicine and ATMPs
In the European Union, certain cell-, tissue- and gene-based medicinal products fall into the category of Advanced Therapy Medicinal Products (ATMPs). These include gene therapy medicinal products, somatic cell therapy medicinal products and tissue-engineered products.
Special requirements for quality, safety and efficacy apply to regular marketing. Terms such as “stem-cell treatment”, “individual cell therapy” or “regenerative therapy” do not replace regulatory assessment.
Examine commercial offers carefully
Terms such as “natural”, “autologous” or “innovative” are not evidence of authorisation, verified quality or clinical efficacy. The Paul-Ehrlich-Institut warns against commercial treatments involving unauthorised ATMPs.
Are autologous procedures automatically safe?
Autologous means that the starting material comes from the same person to whom it is later administered. This may reduce certain immunological risks, but it does not mean that a treatment is free from adverse effects or complications.
Risk assessment depends on factors including collection, processing, sterility, route of administration, target tissue and the patient’s situation. Cell products may also involve unwanted cellular changes, incorrect differentiation, uncontrolled growth or distribution outside the intended tissue.
Even with autologous blood or tissue, collection and administration may cause pain, bleeding, local reactions, infections or injury to adjacent structures. Safety must therefore always be assessed for the specific procedure and indication.
How can reliable claims be recognised?
A technically sound description should state precisely what is used, how extensively the starting material has been processed and for which use data are available.
- The specific product or procedure is clearly identified.
- The cells, tissues, blood components or materials used are stated.
- Regulatory status and scientific stage of development remain clearly distinguishable.
- Potential benefits, limitations, risks and treatment alternatives are explained.
- Labor findings are not presented as proof of clinical efficacy.
- There is no guarantee, no blanket claim of cure and no claim that the procedure is free of adverse effects.
Be cautious with blanket claims
Caution is warranted when a single treatment is claimed to cure numerous unrelated conditions, regenerate them completely or work without risk.
Frequently asked questions about regenerative medicine
Is regenerative medicine the same as stem-cell therapy?
No. Stem-cell therapies are one area within the field. Other cell therapies, tissue engineering, biomaterials, certain gene therapies and often blood-based orthobiologics such as PRP are also included.
Is PRP a stem-cell treatment?
No. PRP is derived from blood and contains specifically processed blood components. It is not a stem-cell preparation.
Can regenerative medicine fully regrow destroyed organs?
For most conditions, this is not currently possible. There are substantial differences between an experimental finding, clinical improvement and complete organ replacement.
Are all treatments advertised as regenerative authorised?
No. “Regenerative” is initially a scientific or marketing description. Authorisation, medical suitability and scientific evaluation must be assessed separately.
Does regenerative medicine replace other treatments?
Not as a general rule. Depending on the procedure, it may form part of standard treatment, be an adjunct or be the subject of clinical research. Its role depends on the diagnosis and the available evidence.
Further professional information
The following pages provide more detail on PRP preparation and centrifugation. Product and technical pages are intended for qualified professionals; the intended purpose, manufacturer’s instructions and internal SOPs remain authoritative.
GuidePRP treatment: procedure, effects and limitationsAn objective assessment of the procedure without promises of success.
Technical toolRCF/RPM calculatorConvert centrifugal force and speed using the rotor radius.
For professionalsComparing PRP tubesTube types, additives and technical distinctions.
For clinics and laboratoriesCentrifuges for PRP and PRFCheck RCF, rotor, tube compatibility and regulatory status.
Sources and scientific basis
- U.S. Food and Drug Administration: Focus Area: Regenerative Medicine.
- European Medicines Agency: Advanced therapy medicinal products: Overview.
- Paul-Ehrlich-Institut: Warning about commercial offers involving unauthorised ATMPs.
- American Academy of Orthopaedic Surgeons: Orthobiologics FAQ.
- Kon E. et al.: Characteristics and clinical application of platelet-rich plasma.
- ESSKA-ORBIT Consensus: Use of injectable orthobiologics for knee osteoarthritis.
- U.S. Food and Drug Administration: Warning about risks from unapproved human cell and tissue products.
Note: This article provides general professional information. It is not a diagnosis, treatment recommendation or recommendation for or against a specific treatment, and it does not replace individual medical assessment.